Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pivotal Phase III, Single Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Investigate the Efficacy and Safety of Single Oral Doses of 10mg, 25mg, 50mg and 70mg GW406381 and 550mg Naproxen Sodium in Subjects With Pain Following Third Molar Tooth Extraction

NCT00114049 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00114049
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00114049 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pivotal Phase III, Single Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Investigate the Efficacy and Safety of Single Oral Doses of 10mg, 25mg, 50mg and 70mg GW406381 and 550mg Naproxen Sodium in Subjects With Pain Following Third Molar Tooth Extraction
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2004
Completion date
April 30, 2005
Enrollment
300
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dental pain, surgery, dental